Cabaletta Bio

Industry · 7 registered clinical trials — 5 currently recruiting.

Status	Trial	Phase	Started
Not Yet Recruiting	RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Multiple Sclerosis - Relapsing Remitting	Phase 1 / Phase 2	2026-06-01
Active Not Recruiting	RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Generalized Myasthenia Gravis (gMG)	Phase 1 / Phase 2	2024-12-17
Recruiting	RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Systemic Sclerosis, Scleroderma	Phase 1 / Phase 2	2024-07-02
Recruiting	RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Activ Systemic Lupus Erythematosus, Lupus Nephritis	Phase 1 / Phase 2	2024-02-16
Recruiting	RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Id Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome	Phase 2 / Phase 3	2023-12-20
Completed	Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis MuSK Myasthenia Gravis	Phase 1	2022-11-23
Recruiting	A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Pemphigus Vulgaris	Phase 1 / Phase 2	2020-09-29